The Mutational Spectrum of Pre- and Post-Neoadjuvant Chemotherapy Triple-Negative Breast Cancers

The Mutational Spectrum of Pre- and Post-Neoadjuvant Chemotherapy Triple-Negative Breast Cancers

The response of triple-negative breast cancer (TNBC) patients to pre-operative (neoadjuvant chemotherapy) is a critical factor of their outcome. To determine the effects of chemotherapy on the tumor genome and to identify mutations associated with chemoresistance and sensitivity, we performed whole...

Full description

Bibliographic Details
Main Authors: Adriana Aguilar-Mahecha, Najmeh Alirezaie, Josiane Lafleur, Eric Bareke, Ewa Przybytkowski, Cathy Lan, Luca Cavallone, Myriam Salem, Manuela Pelmus, Olga Aleynikova, Celia Greenwood, Amanda Lovato, Cristiano Ferrario, Jean-François Boileau, Catalin Mihalcioiu, Josée-Anne Roy, Elizabeth Marcus, Federico Discepola, Jacek Majewski, Mark Basik
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Genes
Subjects:
triple-negative breast cancer
chemoresistance
chemotherapy
genomics
exome sequencing
mutations
Online Access:https://www.mdpi.com/2073-4425/15/1/27

Internet

https://www.mdpi.com/2073-4425/15/1/27

Similar Items